Clinical trials: Pharmacodynamics
Inflammatory Bowel Diseases
First Time in Human Study of Intravenous Interleukin-18 Antibody
GSK1070806 is a humanised monoclonal antibody that blocks a protein present in the body called Interleukin-18. The main purpose of this study is to test GSK1070806 in healthy and obese male subjects with normal immune systems to…
- Trial name
- A18110040 (NCT01035645)
- Testing
- GSK1070806
- Where
- United Kingdom
- Volunteers
- 78 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Advanced Solid Tumors or Lymphomas
A Study of CA-170 (Oral PD-L1, PD-L2 and VISTA Checkpoint Antagonist) in Patients With Advanced Tumors and Lymphomas
CA-170 is a rationally designed and orally available, small molecule that directly targets the Programmed death-ligands 1 and 2 (PD-L1/PD-L2), and V-domain Ig suppressor of T cell activation (VISTA) immune checkpoints and results…
- Trial name
- NCT02812875
- Testing
- CA-170
- Where
- 20 sites in United States, South Korea and 2 more
- Volunteers
- 71 people
- Sponsor
- Curis, Inc.
Advanced Solid Tumors
Study of the AL3810 in the Treatment of Advanced Solid Tumor
This was a monocentric, open label, non-randomised, non-comparative, dose-finding phase I study
- Trial name
- NCT03117101
- Testing
- Lucitanib
- Where
- China
- Volunteers
- 17 people
- Sponsor
- Haihe Biopharma Co., Ltd.
Psoriatic Arthritis
Study of ATI-450 vs Placebo in Patients With Moderate to Severe Psoriatic Arthritis
This is a Phase 2a study to investigate the efficacy, safety, tolerability, PK, and PD of ATI-450 versus placebo in patients with moderate to severe psoriatic arthritis.
- Trial name
- NCT05511519
- Testing
- ATI-450
- Where
- 22 sites in United States, Poland
- Volunteers
- 47 people
- Sponsor
- Aclaris Therapeutics, Inc.
Ulcerative Colitis (UC), Healthy Volunteer
Phase 1 Study Evaluating PALI-2108 in Healthy Volunteers and Ulcerative Colitis Patients.
PALI-2108 is a new oral medication designed to treat ulcerative colitis (UC) by targeting the intestines. It works as a phosphodiesterase-4 (PDE4) inhibitor prodrug, meaning it becomes active only after being processed by…
- Trial name
- NCT06663605
- Testing
- PALI-2108
- Where
- Canada
- Volunteers
- 89 people, healthy volunteers welcome
- Sponsor
- Palisade Bio
Healthy Volunteers
A Trial of SHR2285 in Healthy Subjects
This is a phase 1 open-label study
- Trial name
- NCT04829305
- Testing
- SHR2285
- Where
- Australia
- Volunteers
- 31 people, healthy volunteers welcome
- Sponsor
- Atridia Pty Ltd.
Healthy Volunteers
Study of Evacetrapib (LY2484595) and Warfarin in Healthy Participants
All study participants will receive both warfarin and a study drug called evacetrapib. The main purpose of this study is to look at how much warfarin gets into the blood stream and how long it takes the body to get rid of…
- Trial name
- NCT02161731
- Testing
- Evacetrapib, Warfarin
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Metastatic or Locally Advanced Unresectable Solid Tumors
Tuvusertib (M1774) in Participants With Metastatic or Locally Advanced Unresectable Solid Tumors (DDRiver Solid Tumors 301)
This is an open-label, Phase I, first-in-human (FIH) multicenter, clinical study conducted in multiple parts to establish the safety, tolerability and pharmacokinetic/pharmacodynamic (PK/PD) profile (with and without food) and…
- Trial name
- NCT04170153
- Testing
- M1774, Niraparib
- Where
- 16 sites in United States, China and 3 more
- Volunteers
- 161 people
- Sponsor
- EMD Serono Research & Development Institute, Inc.
Hemophilia A, Hemophilia B
Study of Coagulation Faction VIIa Variant Marzeptacog Alfa (Activated) in Adult Subjects With Hemophilia
This multi-center, open label Phase 1 study will evaluate the pharmacokinetics, pharmacodynamics, and safety of a single IV dose of MarzAA followed by ascending single SC doses of MarzAA in adult subjects with moderate or severe…
- Conditions
- Hemophilia A, Hemophilia B, Hemophilia A With Inhibitor, Hemophilia B With Inhibitor
- Trial name
- NCT04072237
- Testing
- MarzAA (marzeptacog alfa [activated])
- Where
- 5 sites in Bulgaria, Russia
- Volunteers
- 11 people
- Sponsor
- Catalyst Biosciences
Multiple Sclerosis, Relapsing-Remitting
Assessment of Repeat Ascending Doses of GSK2018682 in Healthy Volunteers
The study will evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of repeat ascending doses of GSK2018682.
- Trial name
- P1A114347 (NCT01431937)
- Testing
- GSK2018682
- Where
- 3 sites in Australia
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Peripheral Arterial Disease
Investigation of Safety, Pharmacokinetics and Pharmacodynamics of Different Doses of BIWH 3 in Patients With Chronic Critical Limb Ischaemia
The primary aim of this trial was to investigate the safety of a 6 hour intraarterial infusion of BIWH 3 (pyro-Glu-rhMCP-1) in patients with severe peripheral arterial occlusive disease (PAOD) and chronic Critical Limb Ischaemia…
- Trial name
- COINART-1 (NCT02215824)
- Testing
- BIWH 3
- Volunteers
- 7 people
- Sponsor
- Boehringer Ingelheim
Diabetes Mellitus, Type 2
A Study of LY3305677 in Participants With Type 2 Diabetes
The main purpose of this study is to learn more about the safety and side effects of LY3305677 when it is given as an injection just under the skin to participants with type 2 diabetes.
- Trial name
- NCT03928379
- Testing
- LY3305677
- Where
- Germany
- Volunteers
- 24 people
- Sponsor
- Eli Lilly and Company
Healthy
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GS-248
This is a First in Human (FIH), double-blinded, parallel-group, randomised, placebo-controlled study designed to evaluate the safety, tolerability, PK and PD of single and multiple ascending oral doses of GS-248 in healthy…
- Trial name
- NCT04036227
- Testing
- GS-248
- Where
- Sweden
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- Gesynta Pharma AB
Plaque Psoriasis
A First in Human Study to Evaluate Safety, Tolerability, and Pharmacology of PF-06826647 in Healthy Subjects and Subjects With Plaque Psoriasis
This first in human study will evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of PF-06826647 in healthy subjects and subjects with plaque psoriasis.
- Trial name
- NCT03210961
- Testing
- PF-06826647 tablet, PF-06826647 oral suspension
- Where
- United States
- Volunteers
- 109 people, healthy volunteers welcome
- Sponsor
- Pfizer
Healthy
A Study to Assess the Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of Multiple Ascending Doses of AZD5069 in Healthy Volunteers
The purpose of this study is to explore the safety and tolerability of AZD5069 at steady-state, following twice a day oral dosing in healthy subjects.
- Trial name
- NCT01051505
- Testing
- AZD5069
- Where
- United Kingdom
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Acute Pain
A Phase 1 Dose Escalation Study of Oral VX-708 in Healthy Participants
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of single and multiple ascending doses of VX-708 in healthy participants.
- Trial name
- NCT05347394
- Testing
- VX-708
- Where
- United Kingdom
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Vertex Pharmaceuticals Incorporated
Anemia of Chronic Disease
Pharmacokinetics/Pharmacodynamics of NOX-H94 in the Human Endotoxemia Model
The purpose of this study is to assess the effect of the anti-hepcidin Spiegelmer NOX-H94 on iron homeostasis during systemic inflammation induced by endotoxin.
- Trial name
- NCT01522794
- Testing
- NOX-H94
- Where
- Netherlands
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- TME Pharma AG
Healthy Subjects
Study of TAVO101 in Healthy Volunteers
This is a Phase 1, single ascending dose study designed to investigate TAVO101, administered as an IV infusion in healthy subjects.
- Trial name
- NCT05298046
- Testing
- Experimental: TAVO101
- Where
- Australia
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- Tavotek Biotherapeutics
Drug-drug Interaction
Drug-drug Interactions Between DWC202211 and DWC202212 in Healthy Subjects
An open-label phase 1 study to evaluate pharmacokinetic/pharmacodynamic drug-drug interactions and safety/tolerability of DWC202211 and DWC202212 compared to coadministration in healthy
- Trial name
- DWJ1610 (NCT05699070)
- Testing
- DWC202211 100mg, DWC202212 5mg, DWC202211 100mg + DWC202212 5mg
- Where
- South Korea
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Daewoong Pharmaceutical Co. LTD.
RAS Mutation, Advanced Solid Tumor
A First-in-Human Study Investigating BG-85738 Alone or in Combination With Other Antitumor Agents in Patients With Advanced or Metastatic Solid Tumors With Rat Sarcoma Virus (RAS) Mutations
The purpose of this study is to test if the BG-85738 is safe and if it works in patients with advanced solid tumors with RAS mutations when it is given on its own and in combination.
- Conditions
- RAS Mutation, Advanced Solid Tumor, Metastatic Solid Tumor
- Trial name
- NCT07746141
- Testing
- BG-85738, Tislelizumab, Cetuximab
- Where
- 3 sites in Australia, New Zealand
- Volunteers
- 100 people
- Sponsor
- BeOne Medicines
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.